Controlled clinical evaluations of chlorine dioxide, chlorite and chlorate in man.
To assess the relative safety of chronically administered chlorine water disinfectants in man, a controlled study was undertaken. The clinical evaluation was conducted in the three phases common to investigational drug studies. Phase I, a rising dose tolerance investigation, examined the acute effects of progressively increasing single doses of chlorine disinfectants to normal healthy adult male volunteers. Phase II considered the impact on normal subjects of daily ingestion of the disinfectants at a concentration of 5 mg/l. for twelve consecutive weeks. Persons with a low level of glucose-6-phosphate dehydrogenase may be expected to be especially susceptible to oxidative stress; therefore, in Phase III, chlorite at a concentration of 5 mg/l. was administered daily for twelve consecutive weeks to a small group of potentially at-risk glucose-6-phosphate dehydrogenase-deficient subjects. Physiological impact was assessed by evaluation of a battery of qualitative and quantitative tests. The three phases of this controlled double-blind clinical evaluation of chlorine dioxide and its potential metabolites in human male volunteer subjects were completed uneventfully. There were no obvious undesirable clinical sequellae noted by any of the participating subjects or by the observing medical team. In several cases, statistically significant trends in certain biochemical or physiological parameters were associated with treatment; however, none of these trends was judged to have physiological consequence. One cannot rule out the possibility that, over a longer treatment period, these trends might indeed achieve proportions of clinical importance. However, by the absence of detrimental physiological responses within the limits of the study, the relative safety of oral ingestion of chlorine dioxide and its metabolites, chlorite and chlorate, was demonstrated.
D001769:Blood / Q000187:drug effects; D002704:Chlorates / Q000494:pharmacology*; D002712:Chlorides / Q000494:pharmacology*; D002713:Chlorine / Q000494:pharmacology*; D017606:Chlorine Compounds; D004202:Disinfectants / Q000494:pharmacology*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005953:Glycogen Storage Disease Type I; D006801:Humans; D008297:Male; D010087:Oxides / Q000494:pharmacology*; D013649:Taste
D002704:Chlorates; D002712:Chlorides; D017606:Chlorine Compounds; D004202:Disinfectants; D010087:Oxides; D002713:Chlorine; C025109:chlorine dioxide; C001599:chlorite